Carl Zeiss Meditec AG (CZMWF)
USD 50.46
(0.0%)
USD 50.46
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.2 Billion EUR | 6.93% |
| 2022 | 1.12 Billion EUR | 16.58% |
| 2021 | 967.21 Million EUR | 29.74% |
| 2020 | 745.51 Million EUR | -10.38% |
| 2019 | 831.88 Million EUR | 17.1% |
| 2018 | 710.38 Million EUR | 8.17% |
| 2017 | 656.73 Million EUR | 13.32% |
| 2016 | 579.54 Million EUR | 7.39% |
| 2015 | 539.68 Million EUR | 10.51% |
| 2014 | 488.37 Million EUR | 0.11% |
| 2013 | 487.82 Million EUR | 5.73% |
| 2012 | 461.36 Million EUR | 11.22% |
| 2011 | 414.83 Million EUR | 15.64% |
| 2010 | 358.72 Million EUR | 11.31% |
| 2009 | 322.29 Million EUR | 6.21% |
| 2008 | 303.43 Million EUR | 2.68% |
| 2007 | 295.51 Million EUR | -50.53% |
| 2006 | 597.36 Million EUR | 248.48% |
| 2005 | 171.41 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 727.61 Million EUR | 188.16% |
| 2024 Q1 | 252.5 Million EUR | -25.79% |
| 2024 Q3 | 293.46 Million EUR | -59.67% |
| 2023 Q4 | 340.26 Million EUR | 7.69% |
| 2023 Q2 | 292.17 Million EUR | 13.51% |
| 2023 Q1 | 257.4 Million EUR | -30.3% |
| 2023 Q3 | 315.97 Million EUR | 8.15% |
| 2023 FY | 1.2 Billion EUR | 6.93% |
| 2022 FY | 1.12 Billion EUR | 16.58% |
| 2022 Q1 | 232.8 Million EUR | -13.07% |
| 2022 Q2 | 268.57 Million EUR | 15.37% |
| 2022 Q3 | 256.95 Million EUR | -4.33% |
| 2022 Q4 | 369.29 Million EUR | 43.72% |
| 2021 Q1 | 207.3 Million EUR | -1.34% |
| 2021 Q4 | 267.81 Million EUR | 2.46% |
| 2021 Q3 | 261.37 Million EUR | 13.27% |
| 2021 Q2 | 230.75 Million EUR | 11.31% |
| 2021 FY | 967.21 Million EUR | 29.74% |
| 2020 Q2 | 191.47 Million EUR | -7.19% |
| 2020 FY | 745.51 Million EUR | -10.38% |
| 2020 Q4 | 210.11 Million EUR | 52.63% |
| 2020 Q3 | 137.66 Million EUR | -28.1% |
| 2020 Q1 | 206.3 Million EUR | -16.84% |
| 2019 Q1 | 177.5 Million EUR | -12.34% |
| 2019 Q2 | 195.4 Million EUR | 10.09% |
| 2019 Q3 | 210.83 Million EUR | 7.9% |
| 2019 Q4 | 248.08 Million EUR | 17.67% |
| 2019 FY | 831.88 Million EUR | 17.1% |
| 2018 FY | 710.38 Million EUR | 8.17% |
| 2018 Q1 | 162.9 Million EUR | -8.4% |
| 2018 Q2 | 172.32 Million EUR | 5.79% |
| 2018 Q3 | 172.62 Million EUR | 0.17% |
| 2018 Q4 | 202.48 Million EUR | 17.3% |
| 2017 Q4 | 177.83 Million EUR | 13.49% |
| 2017 Q3 | 156.69 Million EUR | -6.25% |
| 2017 Q2 | 167.14 Million EUR | 7.77% |
| 2017 Q1 | 155.1 Million EUR | -1.1% |
| 2017 FY | 656.73 Million EUR | 13.32% |
| 2016 Q1 | 136.9 Million EUR | -7.42% |
| 2016 Q3 | 137.62 Million EUR | -7.14% |
| 2016 Q4 | 156.82 Million EUR | 13.96% |
| 2016 FY | 579.54 Million EUR | 7.39% |
| 2016 Q2 | 148.19 Million EUR | 8.25% |
| 2015 FY | 539.68 Million EUR | 10.51% |
| 2015 Q4 | 147.87 Million EUR | 13.1% |
| 2015 Q2 | 133.52 Million EUR | 4.69% |
| 2015 Q1 | 127.54 Million EUR | -0.56% |
| 2015 Q3 | 130.74 Million EUR | -2.08% |
| 2014 Q2 | 128.3 Million EUR | 12.59% |
| 2014 FY | 488.37 Million EUR | 0.11% |
| 2014 Q4 | 128.26 Million EUR | 8.85% |
| 2014 Q3 | 117.83 Million EUR | -8.16% |
| 2014 Q1 | 113.96 Million EUR | -17.59% |
| 2013 Q1 | 117.4 Million EUR | -3.57% |
| 2013 FY | 487.82 Million EUR | 5.73% |
| 2013 Q2 | 118.17 Million EUR | 0.65% |
| 2013 Q3 | 113.94 Million EUR | -3.57% |
| 2013 Q4 | 138.29 Million EUR | 21.37% |
| 2012 Q4 | 121.75 Million EUR | 10.81% |
| 2012 Q1 | 110.24 Million EUR | -4.94% |
| 2012 FY | 461.36 Million EUR | 11.22% |
| 2012 Q3 | 109.87 Million EUR | -8.05% |
| 2012 Q2 | 119.49 Million EUR | 8.39% |
| 2011 Q3 | 97.56 Million EUR | -5.37% |
| 2011 Q1 | 98.18 Million EUR | -4.87% |
| 2011 Q2 | 103.11 Million EUR | 5.02% |
| 2011 Q4 | 115.97 Million EUR | 18.86% |
| 2011 FY | 414.83 Million EUR | 15.64% |
| 2010 FY | 358.72 Million EUR | 11.31% |
| 2010 Q2 | 86.81 Million EUR | 9.58% |
| 2010 Q3 | 89.48 Million EUR | 3.08% |
| 2010 Q4 | 103.21 Million EUR | 15.34% |
| 2010 Q1 | 79.22 Million EUR | -2.36% |
| 2009 Q2 | 80.71 Million EUR | -9.87% |
| 2009 Q3 | 70.9 Million EUR | -12.15% |
| 2009 FY | 322.29 Million EUR | 6.21% |
| 2009 Q4 | 81.13 Million EUR | 14.43% |
| 2009 Q1 | 89.54 Million EUR | 0.0% |
| 2008 FY | 303.43 Million EUR | 2.68% |
| 2007 FY | 295.51 Million EUR | -50.53% |
| 2006 FY | 597.36 Million EUR | 248.48% |
| 2005 FY | 171.41 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.69 Million USD | -70864.63% |
| Ansell Limited | 624.8 Million USD | -92.984% |
| Ansell Limited | 624.8 Million USD | -92.984% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 113.94 Million USD | -958.227% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 135.05 Thousand USD | -892695.528% |
| Psykey, Inc. | 415.97 Thousand USD | -289764.079% |
| ConvaTec Group Plc | 1.2 Billion USD | -0.221% |
| ConvaTec Group Plc | 1.17 Billion USD | -2.636% |
| Encision Inc. | 3.13 Million USD | -38349.605% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | - USD | -Infinity% |
| Innovative MedTech Inc. | 794.01 Thousand USD | -151757.085% |
| LifePoint, Inc. | -71.35 Thousand USD | 1689840.464% |
| Medite Cancer Diagnostics, Inc. | -131 Thousand USD | 920531.298% |
| Paradigm Medical Industries, Inc. | 525 Thousand USD | -229569.524% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 603.24 Thousand USD | -199781.473% |
| Reflect Scientific, Inc. | 596.42 Thousand USD | -202066.758% |
| SmileDirectClub, Inc. | 275.84 Million USD | -337.114% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 900.72 Million USD | -33.865% |
| SheerVision, Inc. | 2.17 Million USD | -55314.312% |
| United Health Products, Inc. | -4857.00 USD | 24825403.685% |
| Vasamed, Inc. | -69.38 Thousand USD | 1737814.014% |
| Wearable Health Solutions, Inc. | 267.66 Thousand USD | -450378.774% |
| Yubo International Biotech Limited | 52.65 Thousand USD | -2289964.955% |